Michael K. Keng
Distinguished in Febrile Neutropenia

Dr. Michael K. Keng

Hematology | Oncology
University Of Virginia Physicians Group
1240 Lee St, 
Charlottesville, VA 
Clinical Trials:Currently Recruiting for 1 Trial
Accepting New Patients
Offers Telehealth
Distinguished in Febrile Neutropenia
University Of Virginia Physicians Group
1240 Lee St, 
Charlottesville, VA 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Michael Keng is a Hematologist and an Oncologist in Charlottesville, Virginia. Dr. Keng is rated as a Distinguished provider by MediFind in the treatment of Febrile Neutropenia. His top areas of expertise are Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome (MDS), Acute Myeloblastic Leukemia without Maturation, Bone Marrow Aspiration, and Bone Marrow Transplant. Dr. Keng is currently accepting new patients.

His clinical research consists of co-authoring 38 peer reviewed articles and participating in 11 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, he has co-authored 4 articles in the study of Febrile Neutropenia.

Specialties
Hematology
Oncology
Licenses
Internal Medicine in VA
Hospital Affiliations
Sentara Norfolk General Hospital
University Of Virginia Medical Center
Languages Spoken
English
Mandarin
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem
  • EPO
  • HMO
  • POS
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
HealthKeepers
  • POS
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Piedmont
  • HMO
  • POS
Sentara Healthcare
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE ASSISTANCE PROGRAM
  • MEDICARE MAPD
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 5 Less Insurance Carriers -

Locations

UNIVERSITY OF VIRGINIA PHYSICIANS GROUP
1240 Lee St, Charlottesville, VA 22908

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

10 Clinical Trials

Phase II Trial of Cardioprotective Prophylaxis With Combination of Beta Blocker and Angiotensin-Converting Enzyme Inhibitors During Intensive Chemotherapy for Patients With Newly Diagnosed Acute Myeloid Leukemia
Phase II Trial of Cardioprotective Prophylaxis With Combination of Beta Blocker and Angiotensin-Converting Enzyme Inhibitors During Intensive Chemotherapy for Patients With Newly Diagnosed Acute Myeloid Leukemia
Enrollment Status: Recruiting
Publish Date: February 21, 2025
Intervention Type: Drug
Study Drug: Cardioprotection
Study Phase: Phase 2
A Randomized, Open-label, Controlled, Phase 2 Study of Pevonedistat, Venetoclax, and Azacitidine Versus Venetoclax Plus Azacitidine in Adults With Newly Diagnosed Acute Myeloid Leukemia Who Are Unfit for Intensive Chemotherapy
A Randomized, Open-label, Controlled, Phase 2 Study of Pevonedistat, Venetoclax, and Azacitidine Versus Venetoclax Plus Azacitidine in Adults With Newly Diagnosed Acute Myeloid Leukemia Who Are Unfit for Intensive Chemotherapy
Enrollment Status: Active_not_recruiting
Publish Date: October 08, 2025
Intervention Type: Drug
Study Drugs: Pevonedistat, Venetoclax, Azacitidine
Study Phase: Phase 2
Phase I Study of C6 Ceramide NanoLiposome (CNL) in Patients With Relapsed/Refractory Acute Myeloid Leukemia (RR-AML)
Phase I Study of C6 Ceramide NanoLiposome (CNL) in Patients With Relapsed/Refractory Acute Myeloid Leukemia (RR-AML)
Enrollment Status: Enrolling_by_invitation
Publish Date: October 07, 2025
Intervention Type: Drug
Study Drug: Ceramide NanoLiposome
Study Phase: Phase 1
A Phase 1 Study of Ipilimumab in Combination With Decitabine in Relapsed or Refractory Myelodysplastic Syndrome/Acute Myeloid Leukemia
A Phase 1 Study of Ipilimumab in Combination With Decitabine in Relapsed or Refractory Myelodysplastic Syndrome/Acute Myeloid Leukemia
Enrollment Status: Active_not_recruiting
Publish Date: September 09, 2025
Intervention Type: Drug, Biological
Study Drugs: Decitabine, Ipilimumab
Study Phase: Phase 1
A Randomized, Double-blind, Placebo-controlled Phase III Multi-center Study of Azacitidine With or Without MBG453 for the Treatment of Patients With Intermediate, High or Very High Risk Myelodysplastic Syndrome (MDS) as Per IPSS-R, or Chronic Myelomonocytic Leukemia-2 (CMML-2)
A Randomized, Double-blind, Placebo-controlled Phase III Multi-center Study of Azacitidine With or Without MBG453 for the Treatment of Patients With Intermediate, High or Very High Risk Myelodysplastic Syndrome (MDS) as Per IPSS-R, or Chronic Myelomonocytic Leukemia-2 (CMML-2)
Enrollment Status: Terminated
Publish Date: June 24, 2025
Intervention Type: Drug
Study Drugs: MBG453, Azacitidine
Study Phase: Phase 3
Phase I Study of Inotuzumab Ozogamicin With 3 and 4 Drug Augmented Berlin-Frankfurt-Münster (BFM) Re-Induction for Patients With Relapsed or Refractory B-cell Acute Lymphoblastic Leukemia (B-ALL)
Phase I Study of Inotuzumab Ozogamicin With 3 and 4 Drug Augmented Berlin-Frankfurt-Münster (BFM) Re-Induction for Patients With Relapsed or Refractory B-cell Acute Lymphoblastic Leukemia (B-ALL)
Enrollment Status: Active_not_recruiting
Publish Date: August 22, 2023
Intervention Type: Drug
Study Drugs: Inotuzumab ozogamicin, Prednisone, Daunorubicin, Vincristine, Cytarabine, Methotrexate, Pegaspargase
Study Phase: Phase 1
Phase 3 Multicenter Randomized Trial to Evaluate Efficacy and Safety of CPI-613 in Combination With HD Cyt. and Mito. vs HD Cyt. and Mito. Therapy and Control Sub-groups in Older Patients With R/R AML
Phase 3 Multicenter Randomized Trial to Evaluate Efficacy and Safety of CPI-613 in Combination With HD Cyt. and Mito. vs HD Cyt. and Mito. Therapy and Control Sub-groups in Older Patients With R/R AML
Enrollment Status: Terminated
Publish Date: February 08, 2023
Intervention Type: Drug
Study Drugs: CPI-613, Cytarabine, Mitoxantrone, Etoposide, Fludarabine, Filgrastim
Study Phase: Phase 3
A Phase III, International, Randomized, Controlled Study of Rigosertib Versus Physician's Choice of Treatment in Patients With Myelodysplastic Syndrome After Failure of a Hypomethylating Agent
A Phase III, International, Randomized, Controlled Study of Rigosertib Versus Physician's Choice of Treatment in Patients With Myelodysplastic Syndrome After Failure of a Hypomethylating Agent
Enrollment Status: Terminated
Publish Date: September 26, 2022
Intervention Type: Drug
Study Drug: Rigosertib
Study Phase: Phase 3
An Open-Label Phase 2 Study of Itacitinib (INCB039110) in Combination With Low-Dose Ruxolitinib or Itacitinib Alone Following Ruxolitinib in Subjects With Myelofibrosis
An Open-Label Phase 2 Study of Itacitinib (INCB039110) in Combination With Low-Dose Ruxolitinib or Itacitinib Alone Following Ruxolitinib in Subjects With Myelofibrosis
Enrollment Status: Completed
Publish Date: June 16, 2022
Intervention Type: Drug
Study Drugs: Itacitinib, Ruxolitinib
Study Phase: Phase 2
A Randomized, Double-blind Phase 3 Study of Vadastuximab Talirine (SGN-CD33A) Versus Placebo in Combination With Azacitidine or Decitabine in the Treatment of Older Patients With Newly Diagnosed Acute Myeloid Leukemia (AML)
A Randomized, Double-blind Phase 3 Study of Vadastuximab Talirine (SGN-CD33A) Versus Placebo in Combination With Azacitidine or Decitabine in the Treatment of Older Patients With Newly Diagnosed Acute Myeloid Leukemia (AML)
Enrollment Status: Terminated
Publish Date: December 12, 2018
Intervention Type: Drug
Study Phase: Phase 3
View 9 Less Clinical Trials

38 Total Publications

Improved oral anticancer medication (OAM) adherence/toxicity assessment documentation: A quality improvement initiative.
Improved oral anticancer medication (OAM) adherence/toxicity assessment documentation: A quality improvement initiative.
Journal: Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners
Published: May 13, 2025
Similar Doctors
Maofu Fu
Distinguished in Febrile Neutropenia
Dr. Maofu Fu
Hematology Oncology | Hematology | Oncology
Distinguished in Febrile Neutropenia
Dr. Maofu Fu
Hematology Oncology | Hematology | Oncology

Rmh Medical Group LLC

2008 Health Campus Dr, 
Rockingham, VA 
 (32.2 miles away)
540-689-7000
Languages Spoken:
English
See accepted insurances

Maofu Fu is a Hematologist Oncology specialist and a Hematologist in Rockingham, Virginia. Dr. Fu is rated as a Distinguished provider by MediFind in the treatment of Febrile Neutropenia. His top areas of expertise are Agranulocytosis, Chronic Familial Neutropenia, Inflammatory Breast Cancer, and Febrile Neutropenia.

Advanced in Febrile Neutropenia
Dr. Yogesh K. Gandhi
Hematology Oncology | Hematology | Oncology
Advanced in Febrile Neutropenia
Dr. Yogesh K. Gandhi
Hematology Oncology | Hematology | Oncology

Virginia Cancer Institute Incorporated

1401 Johnston Willis Dr, Suite 100, 
North Chesterfield, VA 
 (61.1 miles away)
804-330-7990
Languages Spoken:
English, Hindi
See accepted insurances
Accepting New Patients
Offers Telehealth

Yogesh Gandhi is a Hematologist Oncology specialist and a Hematologist in North Chesterfield, Virginia. Dr. Gandhi is rated as a Distinguished provider by MediFind in the treatment of Febrile Neutropenia. His top areas of expertise are Thrombocytopenia, Pleuropulmonary Blastoma, Lung Cancer, and Familial Colorectal Cancer. Dr. Gandhi is currently accepting new patients.

Advanced in Febrile Neutropenia
Dr. Elke K. Friedman
Hematology Oncology | Hematology | Oncology
Advanced in Febrile Neutropenia
Dr. Elke K. Friedman
Hematology Oncology | Hematology | Oncology

Virginia Cancer Institute Incorporated

1401 Johnston Willis Dr, Suite 100, 
North Chesterfield, VA 
 (61.1 miles away)
804-330-7990
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Elke Friedman is a Hematologist Oncology specialist and a Hematologist in North Chesterfield, Virginia. Dr. Friedman is rated as a Distinguished provider by MediFind in the treatment of Febrile Neutropenia. Her top areas of expertise are Breast Cancer, Lung Cancer, Paget Disease of the Breast, Bone Marrow Aspiration, and Endoscopy. Dr. Friedman is currently accepting new patients.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Keng's expertise for a condition
ConditionClose
    View All 11 Distinguished Conditions
    View All 12 Advanced Conditions
    View All 24 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile